natgillin/translations-raw huggingface dataset:
Alternativt kan der, for at skylle slangen og sikre tilfredsstillende overførsel af produktet til kredsløbet, gives en injektion til sidst i dialysesessionen via fistelnålslangen, efterfulgt af 10 ml natriumkloridopløsning, 9 mg/ ml (0, 9%).
A lternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection to rinse the tubing and ensure satisfactory injection of the medicinal product into the circulation.
For at sikre optimal respons på
In order to ensure optimum response to erythropoietin, adequate iron stores should be assured: − iron supplementation, e.g.
21 erytropoietin skal det sikres, at der er tilstrækkelige jerndepoter. − Jerntilskud, fx 200- 300 mg/ dag peroralt (100- 200 mg/ dag for pædiatriske patienters vedkommende), anbefales til patienter med kronisk nyresvigt, hvis serumferritinniveau er under 100 ng/ ml. − Peroralt jerntilskud på 200- 300 mg/ dag anbefales til alle cancerpatienter, hvis transferrinmætning er under 20%.
200-300 mg/day orally (100-200 mg/day for paediatric patients) is recommended for chronic renal failure patients whose serum ferritin levels are below 100 ng/ml − oral iron substitution of 200-300 mg/day is recommended for all cancer patients whose transferrin saturation is below 20%.
Alle disse additive faktorer ved anæmi skal også overvejes omhyggeligt, når der træffes beslutning om at øge cancerpatienters erytropoietindosis.
19 All of these additive factors of anaemia should also be carefully considered when deciding to increase the dose of erythropoietin in cancer patients.
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. dosis, dvs. det er praktisk taget "natrium- frit".
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’.
Immunogenicitetsdata for subkutan anvendelse af Silapo hos patienter med risiko for antistof - fremkaldt Pure Red Cell Aplasia (PRCA), dvs. patienter med renal anæmi, er ikke tilstrækkelige.
Immunogenicity data for subcutaneous use of Silapo in patients at risk for antibody-induced Pure Red Cell Aplasia (PRCA), i.e. patients with renal anaemia, are not sufficient.
I kliniske forsøg sås en øget risiko for død og alvorlige kardiovaskulære hændelser, når erytropoiesestimulerende stoffer (ESA' er) blev administreret for at tilstræbe et hæmoglobinniveau, som var højere end 12 g/ dl (7, 5 mmol/ l).
In clinical trials, an increased risk of death and serious cardiovascular events was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
1 g/ dl (0, 62 mmol/ l) pr. måned, og for at minimere risikoen for øget hypertension bør den ikke overstige 2 g/ dl (1, 25 mmol/ l) for at minimere risikoen for, at patienten udvikler eller oplever en forværring af hypertension.
The rate of increase in haemoglobin should be approximately 1 g/dl (0.62 mmol/l) per month and should not exceed 2 g/dl (1.25 mmol/l) per month to minimize the risk of developing or worsening of hypertension.
Hos patienter, hvor der udvikles pludselig mangel på virkning, defineret som et fald i hæmoglobin (1- 2 g/ dl pr. måned) med øget transfusionsbehov, bør der foretages en reticulocyttælling, og de typiske årsager (fx jern -, folat - eller B12- vitaminmangel, aluminiumsforgiftning, infektion eller inflammation, blodtab og hæmolyse) bør undersøges.
In patients developing sudden lack of efficacy, defined by a decrease in haemoglobin (1-2 g/dl per month) with increased need for transfusions, a reticulocyte count should be obtained and typical causes of non-response (e.g. iron, folate, or Vitamin B12-deficiency, aluminium intoxication, infection or inflammation, blood loss, and haemolysis) should be investigated.
Serumelektrolytter skal monitoreres hos patienter med kronisk nyresvigt.
20 electrolytes should be monitored in chronic renal failure patients.
4. 2)
If the rate of increase in haemoglobin exceeds 2 g/dl (1.25 mmol/l) per month or the haemoglobin level exceeds 12 g/dl (7,5 mmol/l), the dose adjustment detailed in section 4.2 should be thoroughly performed to minimise the risk of thrombotic events (see section 4.2).
Dette er især vigtigt hos cancerpatienter med forhøjet risiko for vaskulær trombose, fx ved ovevægt, og patienter, som tidligere har oplevet TVE' er (fx dyb venetrombose eller pulmonal embolisme).
As an increased incidence of thrombotic vascular events (TVEs) has been observed in cancer patients receiving erythropoietic agents (see section 4.8), this risk should be carefully weighed against the benefit to be derived from treatment (with Silapo) particularly in cancer patients with an increased risk of thrombotic vascular events, such as obesity and patients with a prior history of TVEs (e.g. deep venous thrombosis or pulmonary embolism).
I kontrollerede kliniske forsøg har brug af epoetin alfa og andre erytropoiese- stimulerende stoffer (ESA' er) vist: • kortere tid til tumorprogression hos patienter med fremskreden hoved - og halscancer, som får strålebehandling, når stofferne administreres for at tilstræbe et hæmoglobinniveau, som er højere end 14 g/ dl (8, 7 mmol/ l), • kortere samlet overlevelse og flere dødsfald, som tilskrives sygdomsprogression ved 4
In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown: • shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l), • shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5 -8.7 mmol/l), • increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
I lyset af ovenstående er blodtransfusion i nogle kliniske situationer være den foretrukne behandling af anæmi hos patienter med cancer.
21 In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer.
Antistofforårsaget erytroblastopeni (PRCA) er blevet rapporteret efter måneder til års behandling med epoetin alfa.
22 Antibody-mediated erythroblastopenia (PRCA) has been reported after months to years of treatment with epoetin alfa.
Erytropoietins biologiske effektivitet er påvist hos forskellige forsøgsdyr in vivo (normale og anæmiske rotter, polycytæmiske mus).
23 The biological efficacy of erythropoietin has been demonstrated in various animal models in vivo (normal and anaemic rats, polycythaemic mice).
Der er en øget risiko for tromboemboliske hændelser hos patienter med cancer, som behandles med rekombinant humant erytropoietin, og en negativ virkning på samlet overlevelse kan ikke udelukkes.
The re is an increased risk for thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.
5. 2 Farmakokinetiske egenskaber
24 5.2 Pharmacokinetic properties
27 Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
25 Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
STADA Arzneimittel AG Stadastrasse 2- 18 D- 61118 Bad Vilbel Tyskland
26 STADA Arzneimittel AG Stadastrasse 2-18 D-61118 Bad Vilbel Germany
Silapo 3000 IU/ 0, 9 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 3000 IU/0.9ml solution for injection in pre-filled syringe
30 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
Der tilstræbes en hæmoglobinkoncentration på mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l) undtaget hos pædiatriske patienter, hvis hæmoglobinkoncentration bør ligge mellem 9, 5 og 11 g/ dl (5, 9 - 6, 8 mmol/ l).
28 The haemoglobin concentration aimed for is between 10 and 12 g/dl (6.2-7.5 mmol/l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/dl (5.9-6.8 mmol/l).
31 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
De tilgængelige kliniske data tyder på, at patienter med meget lavt initialt hæmoglobin (< 6, 8 g/ dl eller < 4, 25 mmol/ l) kan kræve højere vedligeholdelsesdoser end patienter med initialt hæmoglobin på > 6, 8 g/ dl eller > 4, 25 mmol/ l).
29 The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6.8 g/dl or < 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher > 6.8 g/dl or > 4.25 mmol/l).
32 Hvis hæmoglobinet er steget med mindst 1 g/ dl (0, 62 mmol/ l), eller reticulocyttællingen er steget til ≥ 40. 000 celler/ µl over baseline efter 4 ugers behandling, bør der fortsættes med dosis på 150 IU/ kg 3 gange om ugen eller 450 IU/ kg 1 gang ugentligt.
If the haemoglobin has increased by at least 1 g/dl (0.62 mmol/l) or the reticulocyte count has increased ≥ 40,000 cells/µl above baseline after 4 weeks of treatment, the dose should remain at 150 IU/kg 3 times per week or 450 IU/kg once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
30 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
34 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
a) Intravenøs injektion Dosis skal administreres over mindst 1- 5 minutter, afhængigt af den totale dosis.
31 Intravenous injection The dose should be administered over at least 1-5 minutes, depending on the total dose.
I de fleste tilfælde
All other causes of anaemia (iron deficiency, haemolysis, blood loss, vitamin B12- or folate deficiencies) should be considered and treated prior to initiating and during therapy with Silapo.
35 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
For at sikre optimal respons på erytropoietin skal det sikres, at der er tilstrækkelige jerndepoter. − Jerntilskud, fx 200- 300 mg/ dag peroralt (100- 200 mg/ dag for pædiatriske patienters vedkommende), anbefales til patienter med kronisk nyresvigt, hvis serumferritinniveau er under 100 ng/ ml. − Peroralt jerntilskud på 200- 300 mg/ dag anbefales til alle cancerpatienter, hvis transferrinmætning er under 20%.
200-300 mg/day orally (100-200 mg/day for paediatric patients) is recommended for chronic renal failure patients whose serum ferritin levels are below 100 ng/ml − oral iron substitution of 200-300 mg/day is recommended for all cancer patients whose transferrin saturation is below 20%.
Alle disse additive faktorer ved anæmi skal også overvejes omhyggeligt, når der træffes beslutning om at øge cancerpatienters erytropoietindosis.
32 All of these additive factors of anaemia should also be carefully considered when deciding to increase the dose of erythropoietin in cancer patients.
36 anbefales der regelmæssig monitorering af reticulocyttal Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
Serumelektrolytter skal monitoreres hos patienter med kronisk nyresvigt.
33 electrolytes should be monitored in chronic renal failure patients.
I kontrollerede kliniske forsøg har brug af epoetin alfa og andre erytropoiese- stimulerende stoffer (ESA' er) vist: • kortere tid til tumorprogression hos patienter med fremskreden hoved - og halscancer, som får strålebehandling, når stofferne administreres for at tilstræbe et hæmoglobinniveau, som er højere end 14 g/ dl (8, 7 mmol/ l),
In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown: • shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l), • shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5 -8.7 mmol/l), • increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
I lyset af ovenstående er blodtransfusion i nogle kliniske situationer være den foretrukne behandling af anæmi hos patienter med cancer.
34 In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer.
38 cerebrovaskulær hændelse (cerebral blødning og cerebral infarkt), forbigående iskæmiske anfald, dyb venetrombose, arterietrombose, pulmonal emboli, aneurismer, retinal trombose samt tilstopning af en kunstig nyre hos patienter, der får erythropoietiske midler.
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
Antistofforårsaget erytroblastopeni (PRCA) er blevet rapporteret efter måneder til års behandling med epoetin alfa.
35 Antibody-mediated erythroblastopenia (PRCA) has been reported after months to years of treatment with epoetin alfa.
Erytropoietins biologiske effektivitet er påvist hos forskellige forsøgsdyr in vivo (normale og anæmiske rotter, polycytæmiske mus).
36 The biological efficacy of erythropoietin has been demonstrated in various animal models in vivo (normal and anaemic rats, polycythaemic mice).
40 Der er også foretaget en systematisk gennemgang af mere end 9000 cancerpatienter, som deltog i 57 kliniske forsøg.
A systematic review has also been performed involving more than 9000 cancer patients participating in 57 clinical trials.
5. 2 Farmakokinetiske egenskaber
37 5.2 Pharmacokinetic properties
Dinatriumfosfat- dihydrat Natriumdihydrogenfosfat- dihydrat
Disodium phosphate dihydrate Sodium dihydrogen phosphate dihydrate Sodium chloride Calcium chloride dihydrate Polysorbate 20 Glycine Leucine Isoleucine Threonine Glutamic acid Phenylalanine
41 Natriumklorid Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
38 Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
42 Dette medicinske produkt er kun til engangsbrug.
This medicinal product is for single use only.
Silapo 4000 IU/ 0, 4 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 4000 IU/0.4ml solution for injection in pre-filled syringe
44 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
Der tilstræbes en hæmoglobinkoncentration på mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l) undtaget hos pædiatriske patienter, hvis hæmoglobinkoncentration bør ligge mellem 9, 5 og 11 g/ dl (5, 9 - 6, 8 mmol/ l).
41 The haemoglobin concentration aimed for is between 10 and 12 g/dl (6.2-7.5 mmol/l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/dl (5.9-6.8 mmol/l).
45 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
De tilgængelige kliniske data tyder på, at patienter med meget lavt initialt hæmoglobin (< 6, 8 g/ dl eller < 4, 25 mmol/ l) kan kræve højere vedligeholdelsesdoser end patienter med initialt hæmoglobin på > 6, 8 g/ dl eller > 4, 25 mmol/ l).
42 The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6.8 g/dl or < 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher > 6.8 g/dl or > 4.25 mmol/l).
− Voksne patienter med nyreinsufficiens, der endnu ikke er i dialyse
− Adult patients with renal insufficiency not yet undergoing dialysis
46 med en initialdosis på 450 IU/ kg subkutant 1 gang ugentligt.
Alternatively, Silapo can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
Hvis hæmoglobinet er steget med mindst 1 g/ dl (0, 62 mmol/ l), eller reticulocyttællingen er steget til ≥ 40. 000 celler/ µl over baseline efter 4 ugers behandling, bør der fortsættes med dosis på 150 IU/ kg 3 gange om ugen eller 450 IU/ kg 1 gang ugentligt.
If the haemoglobin has increased by at least 1 g/dl (0.62 mmol/l) or the reticulocyte count has increased ≥ 40,000 cells/µl above baseline after 4 weeks of treatment, the dose should remain at 150 IU/kg 3 times per week or 450 IU/kg once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
43 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
48 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
a) Intravenøs injektion Dosis skal administreres over mindst 1- 5 minutter, afhængigt af den totale dosis.
In travenous injection The dose should be administered over at least 1-5 minutes, depending on the total dose.
49 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
For at sikre optimal respons på erytropoietin skal det sikres, at der er tilstrækkelige jerndepoter. − Jerntilskud, fx 200- 300 mg/ dag peroralt (100- 200 mg/ dag for pædiatriske patienters vedkommende), anbefales til patienter med kronisk nyresvigt, hvis serumferritinniveau er under 100 ng/ ml. − Peroralt jerntilskud på 200- 300 mg/ dag anbefales til alle cancerpatienter, hvis transferrinmætning er under 20%.
200-300 mg/day orally (100-200 mg/day for paediatric patients) is recommended for chronic renal failure patients whose serum ferritin levels are below 100 ng/ml − oral iron substitution of 200-300 mg/day is recommended for all cancer patients whose
50 anbefales der regelmæssig monitorering af reticulocyttal Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
52 cerebrovaskulær hændelse (cerebral blødning og cerebral infarkt), forbigående iskæmiske anfald, dyb venetrombose, arterietrombose, pulmonal emboli, aneurismer, retinal trombose samt tilstopning af en kunstig nyre hos patienter, der får erythropoietiske midler.
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
54 Der er også foretaget en systematisk gennemgang af mere end 9000 cancerpatienter, som deltog i 57 kliniske forsøg.
A systematic review has also been performed involving more than 9000 cancer patients participating in 57 clinical trials.
55 Natriumklorid Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
51 Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
56 Dette medicinske produkt er kun til engangsbrug.
This medicinal product is for single use only.
STADA Arzneimittel AG Stadastrasse 2- 18 D- 61118 Bad Vilbel Tyskland
STADA Arzneimittel AG
Silapo 5000 IU/ 0, 5 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 5000 IU/0.5ml solution for injection in pre-filled syringe
58 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
Der tilstræbes en hæmoglobinkoncentration på mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l) undtaget hos pædiatriske patienter, hvis hæmoglobinkoncentration bør ligge mellem 9, 5 og 11 g/ dl (5, 9 - 6, 8 mmol/ l).
The haemoglobin concentration aimed for is between 10 and 12 g/dl (6.2-7.5 mmol/l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/dl (5.9-6.8 mmol/l).
59 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
De tilgængelige kliniske data tyder på, at patienter med meget lavt initialt hæmoglobin (< 6, 8 g/ dl eller < 4, 25 mmol/ l) kan kræve højere vedligeholdelsesdoser end patienter med initialt hæmoglobin på > 6, 8 g/ dl eller > 4, 25 mmol/ l).
The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6.8 g/dl or < 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher > 6.8 g/dl or > 4.25 mmol/l).
60 med en initialdosis på 450 IU/ kg subkutant 1 gang ugentligt.
Alternatively, Silapo can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
56 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
62 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
63 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
64 anbefales der regelmæssig monitorering af reticulocyttal Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
Epoetiner er vækstfaktorer, som primært stimulerer produktionen af røde blodceller.
Tumour growth potential Epoetins are growth factors that primarily stimulate red blood cell production.
66 cerebrovaskulær hændelse (cerebral blødning og cerebral infarkt), forbigående iskæmiske anfald, dyb venetrombose, arterietrombose, pulmonal emboli, aneurismer, retinal trombose samt tilstopning af en kunstig nyre hos patienter, der får erythropoietiske midler.
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
67 Erytropoietins tilsyneladende molekylvægt er 32000- 40000 Dalton.
62 The apparent molecular weight of erythropoietin is 32,000-40,000 Dalton.
68 Der er også foretaget en systematisk gennemgang af mere end 9000 cancerpatienter, som deltog i 57 kliniske forsøg.
A systematic review has also been performed involving more than 9000 cancer patients participating in 57 clinical trials.